STATEMENT OF NEED
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplant (HSCT), affecting between 40% and 60% of patients and accounting for 15% of posttransplant mortality. The various clinical manifestations of acute and chronic GVHD may be detrimental to a patient’s quality of life. In recent years, advances in the management of other HSCT-related complications such as cytomegalovirus and invasive fungal infections have led to substantial reductions in mortality. However, despite intensive research, GVHD remains a challenge due to its heterogeneity and complex pathogenesis, as well as a lack of well-defined therapeutic targets.
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the management of graft-versus-host disease.
Upon completion of this activity, participants should be able to:
Mark A. Schroeder, MD (Chairperson)
Assistant Professor of Medicine
Washington University School of Medicine
Miguel-Angel Perales, MD
Associate Professor of Medicine
Weill Cornell Medical College
Corey S. Cutler, MD, MPH
Associate Professor of Medicine
Harvard Medical School
There is no fee to participate in or claim CME credit for this activity.
Jointly Provided by
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and i3 Health. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Mark A. Schroeder, MD has served as a consultant for Amgen, Incyte, and Sanofi.
Miguel-Angel Perales, MD has served as a consultant for Incyte, Merck, Novartis, and Seattle Genetics. He has received research support from Incyte and Seattle Genetics.
Corey S. Cutler, MD, MPH has served as a consultant for Bristol-Myers Squibb and Incyte.
Planners and Managers
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. i3 Health planners and managers have no relevant financial relationships to disclose.
INSTRUCTIONS TO RECEIVE CREDIT
UNAPPROVED USE DISCLOSURE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Pharmacyclics and Incyte Corporation.